Innophos, a leading producer of minerals for the nutrition industry, released a new whitepaper highlighting the results of an in-vitro study that demonstrates the superior absorption of Chelamax® Magnesium Bisglycinate and Magnesium Citrate. These findings underscore the benefits of chelated magnesium in developing highly absorbable magnesium supplements.
“This whitepaper presents scientific evidence from our latest in vitro study, showing that Chelamax® chelated magnesium delivers superior absorption in the gastrointestinal tract compared to magnesium oxide and a leading competitor’s product,” said Karen Winkowski, Ph.D., Vice President of Innovation at Innophos. “With our broad range of magnesium products, manufacturers can formulate supplements with improved bioavailability in capsules, tablets, or gummies.”
The in-vitro study compared the bioaccessibility and bioavailability of Chelamax® chelated magnesium against other magnesium sources, such as inorganic magnesium oxide and a competitor’s product. Results revealed significantly higher absorption rates for Chelamax® Magnesium Bisglycinate and Magnesium Citrate.
The whitepaper provides insights on:
• Growing demand for magnesium supplements
• The advantages of increased absorption in Innophos’ magnesium products compared to magnesium oxide
• Performance comparisons between Chelamax® and Albion® Magnesium Bisglycinate
Innophos’ rigorous research and development, including in vitro digestion model studies, confirm the superior absorption of its magnesium products. Offering a variety of magnesium forms for different applications, Innophos also provides technical and formulation support to customers. Chelamax® chelated minerals are supported by an industry-leading 3-step verification process to ensure product quality and integrity. Innophos remains committed to delivering the highest quality, science-backed products, setting new standards in the nutrition industry for validation, transparency, and innovation.
